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Background: Strict compliance with prescribed medication is the key to reducing relapses in schizophrenia. As villagers
in China lack regular access to psychiatrists to supervise compliance, we propose to train village ‘doctors’ (i.e., villagers
with basic medical training and currently operating in villages across China delivering basic clinical and preventive care)
to manage rural patients with schizophrenia with respect to compliance and monitoring symptoms. We hypothesize
that with the necessary training and proper oversight, village doctors can significantly improve drug compliance of
villagers with schizophrenia.
Methods/design: We will conduct a cluster randomized controlled trial in 40 villages in Liuyang, Hunan Province, China,
home to approximately 400 patients with schizophrenia. Half of the villages will be randomized into the treatment
group (village doctor, or VD model) wherein village doctors who have received training in a schizophrenia case
management protocol will manage case records, supervise drug taking, educate patients and families on schizophrenia
and its treatment, and monitor patients for signs of relapse in order to arrange prompt referral. The other 20 villages will
be assigned to the control group (case as usual, or CAU model) wherein patients will be visited by psychiatrists every
two months and receive free antipsychotic medications under an on-going government program, Project 686. These
control patients will receive no other management or follow up from health workers. A baseline survey will be
conducted before the intervention to gather data on patient’s socio-economic status, drug compliance history,
and clinical and health outcome measures. Data will be re-collected 6 and 12 months into the intervention. A
difference-in-difference regression model will be used to detect the program effect on drug compliance and
other outcome measures. A cost-effectiveness analysis will also be conducted to compare the value of the VD
model to that of the CAU group.
Discussion/implications: Lack of specialists is a common problem in resource-scarce areas in China and other
developing countries. The results of this experiment will provide high level evidence on the role of health
workers with relatively limited medical training in managing severe psychiatric disease and other chronic conditions in
developing countries.
Trial registration: ChiCTR-TRC-13003263.
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Schizophrenia affects approximately 0.3% to 0.7% of
people at some point in their lives [1], or 24 million
people worldwide [2], accounting for an estimated 1.1%
of global DALYs (disability-adjusted life years) and 2.8%
of global YLDs (years lived with disability) [3]. Approxi-
mately three-fourths of people with schizophrenia have
ongoing disability due to relapses [4]. Compared with
the general population, schizophrenia patients have sig-
nificantly lower scores in physical and psychological
QoL (Quality of Life) domains [5].
According to an epidemiological survey in four prov-
inces in China during 2001 to 2005, the adjusted preva-
lence of schizophrenia is 7.81 per 1,000; more than half
of the patients live in rural China with little or no access
to professional psychiatrists [6]. Even when treatment is
available to villagers, many remain unaware of, or face
barriers in accessing, treatment.
Drug compliance
Since chlorpromazine was introduced in 1952, antipsy-
chotics have become the principal element of schizophre-
nia treatment, and compliance is key to reducing relapse.
A number of studies outside of China have demonstrated
that partial compliance with antipsychotic medication is a
common problem and is associated with greater risk of
hospitalization [7,8]. In a German study, ‘Needing some-
one to remind them to take their medication’ contributed
to partial compliance in 62% of patients [9]. In a previous
unpublished study conducted by our group, only 20.8% of
villagers with schizophrenia in Liuyang Municipality were
under any kind of supervision of their drug-taking, and
less than 50% of schizophrenia patients took their daily
medication over the past month, consistent with the re-
sults of a study in Qingpu, a municipality near Shanghai,
which showed that 60% of patients fail to comply with
prescribed treatments [10].
Project 686
The ‘Management of Major Psychoses Treatment Pro-
ject,’ funded by the central government and known as
Project 686, aims to improve the treatment of severe
psychoses by dispensing free medications in rural China,
with psychiatric professionals visiting rural communities
every two months to dispense antipsychotics to patients.
Based on our preliminary data, among the 4,000 Project
686 patients registered in Liuyang Municipality, Hunan
Province, as having severe mental disorders – most of
them schizophrenia patients – only approximately 70%
obtained their free antipsychotics in the previous two
months, and for those who got medications, no informa-
tion exists regarding actual use. Despite the availability
of free medication, challenges to compliance persist;
these include engaging family members in compliance,and the two-month interval between psychiatric visits
and dispensation of medications [11].
Case management and village doctors
Community support services commonly available to psy-
chiatric patients in developed countries include drop-in
centers, visits by a community mental health team, facili-
tated employment [9] and support groups. Intensive Case
Management (ICM) is a long-term, community-based
package of care for severely mentally ill people who do
not require immediate admission. Studies comparing vari-
ous models of ICM involving a variety of caregivers such
as family members, mental health workers, psychiatrists-
core teams, and community health workers have demon-
strated the benefit of ICM for patients with schizophrenia
[12,13], including schizophrenic patients in urban areas of
China [14,15]; however, it has been difficult to scale up
these models in rural China, mainly due to lack of human
resources [16]. It is important to develop rational, tar-
geted, and cost-effective risk-reduction strategies to ad-
dress this human resources issue.
Evidence indicates that regular visits by psychiatrists
have a positive effect on treatment compliance of pa-
tients with schizophrenia in rural China [11]. However,
it is not feasible to depend solely on such specialists for
case management given the large population size versus
limited number of psychiatrists in rural China. Lay
health counselors (LHCs) have been shown to be effect-
ive in the treatment of common mental disorders in
low-and middle-income countries (LMICs) [17]. It is
plausible that village ‘doctors’ are the most appropriate
candidates to serve as LHCs in rural China. Village doc-
tors (VDs), despite their title as ‘doctor,’ are individuals
with very basic medical training who provide primary
and preventive care to villagers in almost every village in
China; because VDs are recruited from among the vil-
lagers themselves, they are highly conversant with village
residents’ health conditions and concerns. Earlier re-
search on the effects of directly observed chemotherapy
on tuberculosis, conducted in 1991, showed that satis-
factory treatment adherence and response rates were
achieved using VDs as case managers [18].
Implications of our experiment
This study will integrate a village doctor-assisted case
management model into the existing Project 686 sites in
rural communities of Liuyang. VDs will receive antipsy-
chotics from psychiatrists every two months, store the
medications, manage schizophrenia cases by dispensing
medications to patients and their family members every
week or every day (both intervention strategies will be
tested), counsel patients and family members about the
importance of compliance, address concerns raised by
patients and family members, and monitor patients for
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Using a cluster randomized trial (CRT), we will compare
the effects of this VD model with the care-as-usual
(CAU) model employed in Project 686 in which visiting
psychiatrists dispense drugs to villagers every two months,
but provide no other services. To the best of our know-
ledge, this is the first study using VDs as case managers
for schizophrenia in China. The proposed study has im-
portant implications for improving the management of
schizophrenia patients in over 100 communities enrolled
in Project 686 in China, and will generate findings as to
the effectiveness of involving low level health workers andFigure 1 Conceptual model.family members in managing mental disorders common
in rural China.
Research design and methods
Hypotheses and conceptual model
Hypothesis: Patients in the VD model will have higher
rates of drug compliance and greater social function
than those in the CAU model with respect to symptom
relief, quality of life, hospitalization days and risky
behaviors.
Conceptual model: Figure 1 illustrates the conceptual
model. In this model, VDs exercise five functions of case
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patients to bimonthly psychiatrist visits; storing and dis-
tributing antipsychotics; monitoring drug-taking; and
monitoring patients for symptoms.Methods
Sampling and cluster randomized controlled design
We will conduct a cluster randomized controlled trial
involving a sample of rural schizophrenia patients in
Liuyang Municipality, Hunan Province, China. Criteria
for the sample include:
1. Resided in one of the administrative rural villages of
Liuyang Municipality for the past year.
2. Diagnosed by psychiatrist as having schizophrenia.
3. Registered for free medication under Project 686.
Due to our long time working relationship with the
local government in Liuyang, they have agreed to assist
us in the random selection of villages. A total of 40 ad-
ministrative villages will be selected out of 318 adminis-
trative villages at random. We will use the statistical
software package STATA to generate 40 random num-
bers. All villages will be randomized into two groups
(the intervention arm and the control arm) by block
sampling (block size = four). The randomization will be
based on villages rather than individuals. Due to the na-
ture of our experiment, the allocation will not be blinded
for the service providers, patients and interviewers, but
those who analyze the data will be blinded for the group
information. The co-PI of this project, who is a statisti-
cian, will be responsible for the random allocation se-
quence and the assignment of clusters to interventions.Table 1 Sample size with binary DC
Proportion of patients
achieving DC in the
control group**
Proportion of patients


















*The exercise uses a 5% significance level at a power of 80%, with 10 patients
per cluster as suggested by Project 686 registries.
**The control group proportion of patient achieving DC is based on our
current research in Liuyang.Sample size
To minimize contamination and simplify project man-
agement, we will use one-stage clustered sampling. For a
two-sided significance level of 0.05 and power of 80%,
the sample size is calculated for both the binary variable
Drug Compliance (DC) and the continuous variable
Drug Compliance Score (DCS), with DC referring to a
patient outcome achieving pre-defined compliance or
not, while DCS refers to a score anywhere from 0 (no
compliance) to 10 (full compliance), calculated as the
proportion of the number of drugs actually taken by an
individual divided by the number of drugs prescribed for
that individual over a given period of time. As our previ-
ous study of Project 686 patients with schizophrenia in
Liuyang Municipality showed a 50% compliance rate, or
DC of 0.5, our calculations were based on the need to
detect DC in the range of 0.5 (the current rate) to 0.7
(our hypothesized improvement). In conducting our
sample size analysis, we used software developed by theUniversity of Aberdeen, U.K., specifically for clustered
randomized trials [19].
Sample size with the binary variable drug compliance (DC)
For a cluster randomized trial, the sample size must be
‘inflated’ over that of an individual randomized con-
trolled trial (IRCT), taking into consideration the size of
the cluster as well as the intra-cluster correlation coeffi-
cient (ICC). As we are uncertain about the ICC and the
effect size associated with our intervention, we did a fur-
ther sensitivity analysis (as shown in Table 1) on the
minimum effect size detectable in relation to various
sample sizes and ICCs, assuming a 5% significance level
and 80% power.
From the table above, we can see that in order to detect
a minimum increase in the proportion of patients achiev-
ing DC from 0.5 to 0.6, we will need a sample of at least
860 patients, even assuming a liberal ICC of 0.01. How-
ever, if we can achieve a minimum increase of 0.5 to 0.7,
even at a conservative ICC of 0.1, only 360 patients are
needed for this increase to be detectable. Assuming a pa-
tient drop-out rate of 10%, we arrive at a sample size of
400 patients. Project 686 records indicate that villages in
the cluster have an average of 10 patients per village; con-
sequently, 40 villages will be needed to gather a sample of
400 villagers with schizophrenia.
Sample size with the continuous variable drug compliance
score (DCS)
The continuous variable DCS will also be used in our
data analysis. Our current research in Liuyang indicates
a mean DCR score under Project 686 of 7 out of a total
score of 10; for a significance level of 0.05 at a power of
80%, and a conservative ICC of 0.1, 38 villages with a
total of 380 individuals will be a sample sufficient to de-
tect an effect as small as an increase of 1 in the DCS
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2 additional villages for a total of 40 containing 400 indi-
viduals. Once 40 villages have been selected at random,
they will be further randomized into 20 villages in the
treatment group and 20 in the control group.
Intervention – VD model
In the VD model, village doctors will receive training in
case-management of villagers with schizophrenia using a
protocol developed in the pilot study. The three-day
training will feature mental health knowledge, case-
management skills, and directly observed therapy (DOT).
The format will be tailored to the competencies and ex-
pectations of VDs. Family members of patients will receive
four hours of psycho-educational coaching on how to sup-
port patients and cooperate with the village doctor. VDs
will participate in the case management protocol for one
year and will receive instruction on antipsychotic therapy
from visiting psychiatrists at the time of bimonthly drug
dispensing.
Specifics of the VD model are given below.
Per Project 686 protocol, psychiatrists dispense drugs,
but provide no other services and do not engage family
members in the care of patients. In our VD treatment
model, VDs cooperate with Project 686 psychiatrists and
also reach out to family members to manage patients
and provide the following five services:
1. Develop and maintain case files for every
schizophrenia patient.
2. Store and distribute antipsychotics to family
members on a weekly basis, or directly observe
drug-taking (DOT) at the village clinic on a daily
basis.
3. Accompany patients and family members on
bimonthly visits to psychiatrists for drug
dispensation in order to participate in assessing
patients’ mental status and explain treatment plans
to patients and their families.
4. Record patients’ medication-taking behavior weekly.
5. Identify signs of relapse in order to provide prompt
referral services.
To incentivize VDs’ participation, we have obtained
preliminary approval to include VDs’ case management
efforts in their annual performance review, and will pro-
vide a modest fee for VDs for their time and effort.
Procedures
Following a pilot study (see Section below), 40 villages (ex-
cluding the pilot study villages) will be randomly selected
in Liuyang Municipality. We will conduct a baseline sur-
vey of patients with schizophrenia in the villages, collect-
ing data on social demographics, compliance rates, clinicalcharacteristics, and outcome measures. Researchers will
explain the research to participants and obtain written in-
formed consent from both patients and family member.
And after the randomization, VDs and family members
of patients will receive training and education in the
12-month case management protocol as noted in Section
above. Researchers will visit VDs every month during the
first three months of the study and every three months
thereafter for the remaining nine months of the study,
obtaining feedback and giving follow-up instructions, and
recording and monitoring VDs’ case management work
via questionnaire.
In the CAU model, control villages will continue to re-
ceive bimonthly visits by psychiatric professionals, who
will dispense free antipsychotics per existing Project 686
protocol. No other interventions will be introduced.
Follow-up interviews will be conducted with patients
in both VD and CAU model villages at 6 months and 12
months into the intervention, collecting the same data
as that collected at baseline (see below).
Instruments
Four types of statistics will be collected at baseline and
at 6 months and 12 months into the study:
Socio-demographic characteristics: age, sex, education
level, marital status, work, economic status, domestic
situation (living alone, with family, or with friends).
Clinical characteristics: years of illness, number of bed
days in psychiatric hospital in previous two years.
Compliance: This is our primary dependent variable
measure. The binary variable Drug Compliance (DC)
will be recorded by interviewing patients and their fam-
ily members. We define as ‘compliant’ patients who, over
the past month, have taken all pills as prescribed; other-
wise, patients are recorded as ‘non-compliant.’ We will
report 1-month, 3-month, 6-month and 12-month com-
pliance as the proportion of patients achieving compli-
ance over the total number of patients. In addition, a
continuous variable Drug Compliance Score (DCS) will
be used to measure medication compliance. The DCS
score will be measured by dividing the actual number of
pills taken by the total number of pills prescribed multi-
plied by 10 over a given period of time, with scores ran-
ging from 0 (complete non-compliance) to 10 (complete
compliance). For example, if a patient over the past
month took 20 pills out of 100 prescribed, his compli-
ance will be (20/100) × 10 = 2 for the past month.
Clinical/outcome measures: Four types of measures
will be collected.
Symptoms score: Schizophrenia is often described in
terms of positive and negative (or deficit) symptoms.
Negative symptoms respond less well to medication [20],
particularly to the antipsychotics that are typically used
for cases in our research. Therefore, we will concentrate
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with medication compliance. The Brief Psychiatric Rating
Scale (BPRS) will be used to evaluate positive symptoms.
The BPRS is an 18-item rating scale that has been widely
used in psychiatric practice and research in China, and
has good to excellent reliability and validity.
Social functions: We will use the global assessment of
functioning (GAF) scale, in which a score of 0 to100 is
converted to a disability weight ([100-GAF score]/100).
Patients with a disability weight of 0.40 or greater are
classified as moderately to severely disabled.
Quality of life score: We will use the QALY weights
developed by Lenert et al. [21].
Hospitalization rate: Time to readmission is measured
by a product-limit formula. Hospitalization rate is the
proportion of patients with schizophrenia who warrant
hospital admission. Data on hospitalization will be col-
lected from patient medical records.
Incidence of risky behavior: Risky behaviors in schizo-
phrenia include suicide, self-harm, and wandering. We
will collect incidence data from family members of pa-
tients as to the number of times the above-mentioned
behaviors have occurred in the past year.
Statistical methods
Comparison between VD model and CAU model
T, Chi-square and various kinds of regression tests will
be used to compare DCR (binary variable), DCS (con-
tinuous variable), and hospitalization (continuous vari-
able) and incidence of risky behavior (binary variable)
rates between the VD and CAU models. Repeated ana-
lyses of variance will be used to compare psychiatric
symptoms and social function (continuous variable)
scores between the two groups.
We will use a difference-in-difference regression model
with one treatment variable and additional regressors as con-
trol variables (see below). Insofar as perfect randomization
and program execution are rarely achieved, we make use of
an equation with a difference-in-difference Ordinary Least
Square (OLS) estimator with additional regressors to esti-
mate population true coefficients. The example below uses
DCS as the dependent variable.
ΔDCSi ¼ β0 þ β1VDmodeli þ β2SocialEconDemogi
þ β3SeverityIllnessi þ β4FamilyCarei þ ui
ΔDCS: This is the value of DCSi for the ith individual
at the end of the experiment minus the value of DCSi at
the start, or the change. DCS is the Drug Compliance
Score, a continuous variable ranging from 0-10, with 0
indicating zero compliance and 10 full compliance.
Treatment (VDmodel): This is a binary variable indi-
cating whether an individual is enrolled in the treatment
model (VD) or the control group (CAU). Treatment = 1if an individual is in the treatment group and 0 for indi-
viduals in the control.
Social EconDemog: This refers to social, economic and
demographic characteristics that can be plugged into the
model as additional control variables for analysis.
Illness Severity: This is a composite of variables relat-
ing to illness severity such as number of years an indi-
vidual has been diagnosed with schizophrenia before the
start of our program, and days of hospitalization due to
schizophrenia over the two years before the start of the
program.
β4FamilyCare i: This variable indicates the level of care
an individual receives from his or her family.
ui: This is the residual of all other determinants of DCS.
In the above equation, β1 indicates program effect,
i.e., the effectiveness of village doctors in managing
villagers with schizophrenia as measured by the aver-
age change in DCS for those in the treatment group
(VD) minus the average change in DCS for those in
the control group (CAU).
There are several advantages to using this model. First,
the coefficient in which we are most interested, β1, is
more efficient than other estimators as it has a smaller
variance or standard error than a simple difference esti-
mator when unobserved determinants of DCS persist
over time for a given individual. Second, this model
eliminates possible pre-program differences in DCS be-
tween the treatment and control groups; for example,
while using cluster randomization, we may not achieve
true randomization at the individual level since it is pos-
sible (though unlikely) that all eligible individuals within
a cluster could be assigned to a treatment or to a control
group. Finally, the difference-in-difference equation allows
for additional variables to be added to the treatment vari-
able in the VD group. As these added regressors are
possible determinants of the dependent variable DCS,
including them improves the efficiency of the OLS es-
timator, β1, which is the coefficient for program effect,
thus addressing: potential bias introduced by imperfect
randomization; partial compliance wherein patients
with more severe illness in the VD group may at times
elect not to comply with village doctors’ care, while pa-
tients with milder disease or more supportive family
members in the CAU group may, of their own initia-
tive, seek care from their village doctors; and attrition
as severely ill patients are lost to follow-up (depending
on the data collected, we will seek instrumental vari-
ables to address bias introduced by drop-outs). That
said, we anticipate a high take-up rate by patients in
rural Liuyang because the free antipsychotics program
has been operating in the municipality for several years
and has been well accepted by patients and their fam-
ilies. Given past experience in Liuyang, we anticipate a
drop-out rate of 10% over the course of the study.
Gong et al. Implementation Science 2014, 9:13 Page 7 of 10
http://www.implementationscience.com/content/9/1/13Cost effectiveness analysis
Addressing whether the program is cost-effective is also
important. Our cost-utility analysis will assess the cost per
quality-adjusted life-years (QALY) added with the pro-
gram. The analysis is from the societal perspective such
that any cost charged to any stakeholder is counted, in-
cluding volunteer time. The lower the cost per QALY, the
more cost-effective the program is. In the present
study, costs for treating schizophrenia and controlling
symptoms, e.g. VD and family members’ time as well
as medication costs, will be weighed against averted
costs, e.g. medical costs of hospitalization and the so-
cial costs incurred by the disruption of family and vil-
lage life by untreated patients. The QUALY costs – and
savings – of the proposed study can then be weighed
relative to other medical interventions.
We will estimate QALY using a Markov Chain ap-
proach, largely modifying and following Garcia-Ruiz et al.
[22]. As in Garcia-Ruiz, our model will allow for relapses
into schizophrenia while taking medication, discontinuing
medication due to side effects, or discontinuing medica-
tion due to other reasons.
Pilot study
A pilot study will be conducted in two villages (A and B)
before the main project.
Structured training course
During the pilot study, we will develop a three-day train-
ing course for VDs and a four-hour research study and
treatment familiarization course for families of patients
with schizophrenia. These initiatives will build on our
previous experience in developing training courses and
will also enlist expert consultation. The training courses
will be implemented in the two pilot study villages to be
selected by PI, matching the two villages with as much
similar characteristics as possible, and feedback from ex-
perts and trainees will be collected for continuous qual-
ity improvement.
Methods for distributing antipsychotics
In village A, the VD will distribute antipsychotics to
family members on a weekly basis for two months. In
village B, patients will receive their medicine in the vil-
lage clinic every day for DOT. These medication distri-
bution methods will be alternated in villages A and B
after two months, so that the total time during which
medication distribution is facilitated by VDs will be four
months. Feedback on these distribution methods will be
collected from participating patients, family members,
and VDs in structured focus group discussions. The
more feasible distribution method will be determined
based on these structured discussions.Case-management protocol
A preliminary case-management protocol for VDs will
be implemented in villages A and B for four months.
The protocol for VD management of patients with
schizophrenia will be finalized following the structured
discussions described above.
Reliability and validity of instruments
The reliability and validity of instruments to be used in
the baseline survey and in follow-up investigations will be
examined during the pilot study. Reliability measures will
include test-retest reliability and internal consistency.
Validity measures will include structural validity, dif-
ferences among patients with different age and educa-
tional levels, and changes observed consequent to VD
case management.
Sample size validation
Assumptions in calculating sample size will be tested
using data collected in the pilot. We will adjust our final
sample size accordingly and as necessary.
Figure 2 below summaries the main activities for the
pilot and main studies.
Trial status
The trial started its pilot phase in Sankou and Gugang town-
ships of Liuyang Municipality in July 2013. We are currently
in the process of collecting the data from the pilot study.
Discussion
This randomized controlled study of the role of VDs in
managing severely ill mental health patients is the first of
its kind in China. We anticipate that VDs living and prac-
ticing close to the community, despite their relatively lim-
ited medical training, will prove to be valuable assets in
improving mental healthcare in low resource areas. Fur-
thermore, this research will help define the role of alterna-
tive healthcare workers and lay persons more generally in
managing chronic illnesses in areas where access to spe-
cialist care is either difficult or unavailable. As this problem
is not unique to China, lessons gleaned from this study
will likely extend to populations around the globe.
Previous research has suggested various means to im-
prove drug compliance [23]:
1. Empowering patients by involving them in treatment
decisions.
2. Improving supervision of patients through a
multi-disciplinary team approach.
3. Keeping drug regimes simple and giving close
attention to side effects.
4. Improving patient education on medication and side
effects, and involving family and friends of the
patient in treatment and compliance.
Figure 2 Main activities of pilots and main project.
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aspects of treatment by reducing waiting time,
selecting treatment locations preferred by the
patient, arranging transportation, and so forth.
Our intervention was designed with these means in
mind, with VDs playing a pivotal role in facilitating co-
operation among patients, family members, and psy-
chiatrists, while themselves providing essential services
in educating patients and their families, supervising
treatment (particularly with respect to patients’ drug
taking) and monitoring for signs of relapse and other
developments requiring referral. Living and working in
the same village as patients and their families, VDs are
easily accessible to patients and likely have already
established a bond of trust. With proper training in
case management, their current role as providers of
basic medical and preventive care can be expanded to
include patient education in, and cooperative treat-
ment and monitoring of, mental illness, thus extending
the reach of psychiatry into the rural environment.
While our analysis is not sufficiently fine-grained to
detect the effect of the various individual strategies
listed above on drug compliance, it will deliver sub-
stantial data on how VDs function in delivering, coord-
inating and facilitating a case management protocol in
which these strategies are mobilized to improve patient
outcomes.
The strength of the proposed RCT is its potential to
provide high level evidence on the role of VDs in man-
aging schizophrenia, but the proposal has limitations. Our
chief concern has been documenting compliance which,
when self-reported by patients, is problematic insofar as
patients may be reluctant to report poor compliance. With
VDs counting pills, directly observing drug-taking and
corroborating compliance with family members, we ex-
pect that our study will more likely assess the true treat-
ment situation. A further limitation is that our project
piggy-backs on the existing free antipsychotic medication
program in Liuyang Municipality; thus, the results may
not be fully generalizable to populations in communities
where Project 686 has not been implemented. Finally, we
must recognize that the Chinese healthcare system has yet
to compensate VDs financially for the extra effort involved
in providing mental health services. We are hopeful that
our research will provide evidence of the public health
benefit and cost-effectiveness of employing VDs in the
management of serious mental health problems, which
may in turn facilitate policy changes in creating system in-
centives for care-givers who provide these services.
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